The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

An Okanagan man is suing Interior Health and several doctors for malpractice after a cancer misdiagnosis delayed care and ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114. See why I rate ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia following head and neck cancer treatment.

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

An Okanagan man is suing Interior Health and several doctors for malpractice after a cancer misdiagnosis delayed care and ...

Researchers at the University of Kentucky have introduced a novel microscopy technique that could revolutionize cancer research by providing an ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

A South Carolina native and two-time Super Bowl champion celebrated a life win recently. Jim Stuckey is cancer-free after an extensive battle with head and neck ...

Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase I ...